Loading patent…
AssigneeAlnylam Pharmaceuticals, Inc.
InventorsMatthias John, Stefan Limmer, Hans-Peter Vornlocher, Roland Kreutzer
Estimating the term…
The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is less that 30 nucleotides in length and which is substantially identical to at least a part of a 3′-untranslated region (3′-UTR) of a (+) strand RNA virus, such as HCV, as well as pharmaceutical compositions comprising the dsRNA, together with a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for treating infections and diseases caused by the replication or activity of the (+) strand RNA virus, as well as methods for inhibiting viral replication.
A double-stranded ribonucleic acid (dsRNA) for inhibiting the replication of a (+) strand RNA virus, wherein the dsRNA comprises a sense RNA strand comprising a the nucleotide sequence of SEQ ID NO:4 and a complementary RNA strand comprising the nucleotide sequence of SEQ ID NO:5, and wherein the dsRNA is less than 30 base pairs in length.
A pharmaceutical composition for inhibiting the replication of a (+) strand RNA virus in an organism, comprising a dsRNA and a pharmaceutically acceptable carrier, wherein the dsRNA comprises a sense RNA strand comprising the nucleotide sequence of SEQ ID NO:4 and a complementary RNA strand comprising the nucleotide sequence of SEQ ID NO:5, and wherein the dsRNA is less than 30 base pairs in length.
Dependencies are inferred from the claim text.